A comparison of a moderate with moderate-high intensity oral anticoagulant treatment in patients with mechanical heart valve prostheses

Thrombosis and Haemostasis

Volumn 77, Issue 5, 1997, Pages 839-844

  Pengo, Vittorio ^a,b   Barbero, Fabio ^a   Banzato, Alberto ^a   Garelli, Elisabetta ^a   Noventa, Franco ^a   Biasiolo, Alessandra ^a   Zasso, Antonella ^a   Dalla Volta, Sergio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Department of Medical Oncology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEART VALVE PROSTHESIS; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THROMBOEMBOLISM; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT PLANNING; VASCULAR DISEASE;

EID: 0030982677     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1656064     Document Type: Article

References (43)

1. Duvoisin GE, Brandenburg RO, McGoon DC. Factors affecting thromboembolism associated with prosthetic heart valves. Circulation 1967; 35 (suppl.1):70-6.
2. Yeh TJ, Anabtawi IN, Cornell VE, Ellison RG. Influence of rhythm and anticoagulation upon the incidence of embolization associated with Starr-Edwards prostheses. Circulation 1967; 35 (suppl.1): 77-81.
3. Akbarian M, Austen WG, Yurchak PM, Scannel JG. Thromboembolic complications of prosthetic cardiac valves. Circulation 1968; 37: 826-31.
4. Baudet EM, Oca CC, Roques XF, Laborde MN, Hafez AS, Collot MA, Ghidoni IM. A 51/2 year experience with the St. Jude Medical cardiac valve prosthesis. Early and late results of 737 valve replacements in 671 patients. J Thorac Cardiovasc Surg 1985; 90: 137-44.
5. Björk VO, Henze A. Management of thromboembolism after aortic valve replacement with the Björk-Shiley tilting disc valve. Scand J Thorac Cardiovasc Surg 1975; 9: 183-91.
6. Dale J, Myhre E. Can acetylsalicylic acid alone prevent arterial thromboembolism: a pilot study in patients with aortic ball valve prostheses. Acta Med Scand 1981; 645: 73-7.
7. Moggio RA, Hammond GL, Stansel HC Jr, Ghenn W. Incidence of emboli with cloth-covered Starr-Edwards valve without anticoagulation and with varying forms of anticoagulation: analysis of 183 patients followed for 31/2 years. J Thorac Cardiovasc Surg 1978; 75: 296-9.
8. El Makhlouf A, Friedli B, Oberhansli I, Rouge JC, Faidutti B. Prosthetic heart valve replacement in children. Results and follow-up of 273 patients. J Thorac Cardiovasc Surg 1987; 93: 80-5.
9. Brott WH, Zajtchuk R, Bowen TE, Davia J, Green DC. Dipyridamole-aspirin as thromboembolic prophylaxis in patients with aortic valve prosthesis. Prospective study with the Model 2320 Starr-Edwards prosthesis. J Thorac Cardiovasc Surg 1981; 81: 632-5.
10. Hartz RS, LoCicero J III, Kucich V, Deboer A, O'Mara S, Meyers SN, Michaelis LL. Comparative study of warfarin versus antiplatelet therapy in patients with a St. Jude Medical valve in the aortic position. J Thorac Cardiovasc Surg 1986; 92: 684-90.
11. Ribeiro PA, Al Zaibag MA, Idris M, Al Kasab S, Davies G, Mashat E, Wareham E, Al Fagih M. Antiplatelet drugs and the incidence of thromboembolic complications of the St.Jude Medical aortic prosthesis in patients with rheumatic heart disease. J Thorac Cardiovasc Surg 1986; 91: 92-8.
12. Edmunds LH. Thrombotic and bleeding complications of prosthetic heart valves. Ann Thorac Surg 1987; 44: 430-45.
13. Fuster V, Badimon L, Badimon JJ, Chesebro J. Prevention of thromboembolism induced by prosthetic valves. Semin Thromb Hemost 1988; 14: 50-8.
14. Stein PD, Kantrowitz A. Antithrombotic therapy in mechanical and biological prosthetic heart valves and saphenous vein bypass grafts. Chest 1989; 95 (suppl2): 107-17.
15. Loeliger EA, Poller L, Samama M, Thomson JM, Van den Besselaar AMHP, Vermylen J, Verstraete M. Questions and answers on prothrombin time standardisation in oral anticoagulant control. Thromb Haemost 1985; 54:515-7.
16. British Society for Haemotology. British Committee for Standards in Haematology, Haemostasis and Thrombosis Task Force. Guidelines on oral anticoagulation: second edition. J Clin Pathol 1990; 43: 177-83.
17. Loeliger EA, Lewis SM. Progress in laboratory control of oral anticoagulants. Lancet 1982; 2: 318-20.
18. Boekhout Mussert MJ, Briët E, Van Brummelen P, Lemkes HHPJ, Loeliger EA. Arterial thromboembolic complication with aortic ball valve prosthesis. Am Heart J 1978; 95: 270-7.
19. Saour JN, Sieck JO, Mamo LAR, Gallus AS. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990; 322: 428-32.
20. Kuntze CEE, Ebels T, Eijgelaar A, van der Heide JNH. Rates of thromboembolism with three different mechanical heart valve prostheses: randomised study. Lancet 1989; 19: 514-7.
21. Pengo V, Banzato A, Garelli E, Zasso A, Biasiolo A. Reversal of excessive effect of regular anticoagulation: low oral dose of phylonadione (Vitamin K1) compared to warfarin discontinuation. Blood Coag Fibrinolysis 1993: 4: 739-41.
22. Kerin NZ, Blevins RD, Goldman L, Faitel K, Rubenfire M. The incidence, magnitude, and time course of the amiodarone-warfarin interaction. Arch Intern Med 1988; 148: 1779-81.
23. Berengo M, Pengo V, Peruzzi P, Banzato A, Schivazappa L. Organizational model for dental treatment of patients on antithrombotic prophylaxis with oral anticoagulants. G Stomatol Ortognatodonzia 1989; 8: 38-9.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
25. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-70.
26. Rosendaal FR, Cannegieter SC, van der Meer FJM, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-9.
27. Loeliger EA. Therapeutic target values in oral anticoagulation - Justification of Dutch policy and a warning against the so-called moderate intensity regimens. Ann Hematol 1992; 64: 60-5.
28. Broekmans AW, Loeliger EA. High complication and failure rates of anti-coagulant therapy are avoidable. Z Kardiol 1986; 75 (Suppl 2): 298-301.
29. Loeliger EA. Laboratory control, optimal therapeutic ranges and therapeutic quality control in oral anticoagulation. Acta Haematol 1985; 74: 125-31.
30. Stein PD, Alpert JS, Copeland J, Dalen JE, Goldman S, Turpie AGG. Anti-thrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1992;102 (suppl. 4): 445-55.
31. Sethia B, Turner MA, Lewis S, Rodger RA, Bain WH. Fourteen years' experience with the Björk-Shiley tilting disc prosthesis. J Thorac Cardiovasc Surg 1986; 91: 350-61.
32. Vogt S, Hoffmann A, Roth J, Dubach P, Bertschmann W, Hasse J, Gradel E, Stulz P, Burckhardt D. Heart valve replacement with the Björk-Shiley and St. Jude Medical prostheses: a randomized comparison in 178 patients. Eur Heart J 1990; 11: 583-91.
33. DiSesa VJ, Collins JJ Jr, Cohn LH. Hematological complications with the St. Jude valve and reduced-dose coumadin. Ann Thorac Surg 1989; 48: 280-3.
34. Kopf GS, Hammond GL, Geha AS, Elefteriades J, Hashim SW. Long-term performance of the St. Jude Medical valve: low incidence of thromboembolism and hemorrhagic complications with modest doses of warfarin. Circulation 1987; 76 (suppl. 3): 132-6.
35. Altman R, Rouvier J, Gurfinkel E, D'Ortencio O, Manzanel R, de La Fuente L, Favaloro RG. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 1991; 101: 427-31.
36. Turpie AGG, Gent M, Laupacis A, Latour Y, Gunstensen J, Basile F, Klimek M, Hirsh J. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993; 329: 524-9.
37. Grunkemeier GL, Rahimtoola SH. Artificial heart valves. Annu Rev Med 1990; 41: 251-63.
38. Pleigh PS, DiSesa DJ, Cohn LH, Collins JJ. Neurological and ophthalmological phenomena after aortic conduit surgery. Circulation 1990; 82 (suppl IV): 47-50.
39. Wilson DB, Dunn MI, Hassanein K. Low intensity anticoagulation in mechanical cardiac prosthetic valves. Chest 1991; 100: 1553-7.
40. Levine NM, Hirsh J, Landefeld S, Raskob G. Hemorrhagic complications of anticoagulant treatment. Chest 1992; 102 (suppl. 4): 352-63.
41. Lancaster TR, Singer DE, Sheehan MA, Oertel LB, Maraventano SW, Hughes RA, Kistler JP. The impact of long-term warfarin therapy on quality of life. Evidence from a randomized trial. Arch Intern Med 1991; 151: 1944-9.
42. Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, White RH. Risk factors for complication of chronic anticoagulation. Ann Intern Med 1993; 118: 511-20.
43. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJM, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-7.